History

Bioindustry’ on NexP™-based long-acting human growth hormone (ALT-P1) development project by Ministry of Trade, Industry and Energy of Korea
DECSelected as 2017 Excellent Bio-field Company by Ministry of Industry of Korea (Received Minister’s Award by Ministry of Trade, Industry and Energy)
OCTCommenced Clinical Phase II for long-acting human growth hormone (ALT-P1) based on original NexP™ platform technology
OCTBreast cancer antibody-drug conjugate (ADC) selected as Pan-Ministry New Drug Development Project Group for National New Drug Development Project
SEPSigned business agreement for joint ADC development (with Levena Biopharma of China)
AUGCertified as a venture company (Fifth, Venture Investment Company, No. 20170300402)
AUGADC biobetter (ALT-P7) for breast cancer treatment commenced Korea’s first Clinical Phase I
JUNReceived Grand Award at Maekyung Star Audition
MARSigned licensing-out contract for Herceptin biosimilar (with Qilu of China)
JANSelected as a “firm with superior intellectual capacity expertise” (Ministry of Trade, Industry and Energy of Korea)
NOVCEO Soon Jae Park, PhD receives Intellectual Property Entrepreneur Award (Korea Invention Promotion Association Chairman’s Award)
SEPSelected as merit company for regional industry promotion (Awarded by Ministry of Trade, Industry and Energy of Korea)
JULSelected as 2016 National R&D Top 100 Excellence Performance (Ministry of Science of Korea, ICT and Future Planning)
JUNCEO Soon Jae Park, PhD selected as Man of Merit for development of biomedicine industry (Awarded by Minister of Food and Drug Safety of Korea)
JUNSelected for ‘Technology development project for firms with superior intellectual capacity expertise’ on NexP™-based hemophilia medicine development project by Ministry of Trade, Industry and Energy of Korea
APRSelected as 2016 Youth-friendly strong small business (Ministry of Employment and Labor of Korea)
OCTSigned licensing-out contract for ADC breast cancer medicine (ALT-P7) (with 3SBio of China)
SEPCompleted Clinical Phase I testing for long-acting human growth hormone (ALT-P1)
AUGCertified as a venture company (Fourth, Venture Investment Company, No. 20150300299)
DECListed on KOSDAQ
FEBSelected as “IP Star Company” (Korean Intellectual Property Office)
MAYProject for development of antibody biosimilar for curing arthritis selected as Project for Nurturing Strong Global Small Business by Small and Medium Business Administration of Korea
APRSelected as a military service waived company (Research center affiliated with venture company) (Military Manpower Administration of Korea)
MARAltos Bioscience, a subsidiary, signed licensing-out contract for animal medicine (with UQ of Brazil)
AUGCertified as a venture company (Second, Venture Investment Company, No. 20110300189)
JUNSigned licensing-out contract for two antibody biosimilar assets (with Cristalia of Brazil)
JUNProject for developing biobetter on breast cancer antibody-drug conjugate medicine selected as Industry Convergence Original Technology Development Project by Ministry of Knowledge Economy of Korea
JUNSelected as Regional Star Company (Ministry of Knowledge Economy of Korea)
SEPSigned licensing-out contract for long-acting human growth hormone (with CJ CheilJedang of Korea)
JUNCEO Soon Jae Park, PhD inaugurated
JULResearch center confirmed for the company affiliation (Korea Industrial Technology Association, No. 20092108282)
MAYCompany establishment